Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, US
Article content
ST. PAUL, Minn. — Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania.
Article content
Article content
The new facility is designed to support biopharma customers with applications and process development for the purification of biotherapeutic molecules, providing comprehensive technical support to biopharmaceutical companies and contract manufacturers operating from small-scale to full commercial production. This new development location is well positioned in the Eastern U.S., close to many large pharmaceutical operations and a hub of bioprocessing innovation.
Article content
The lab is equipped with high-throughput process development tools and manufacturing scale chromatography columns, enabling biotech firms to receive turnkey support for process development. Large biopharma companies can utilize the applications lab throughout the entire development cycle, from early to late stage and commercialization; including characterizing alternative resins to help reduce manufacturing costs and support with regulatory submissions.
Article content
'Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world,' said Jennifer Sorrells, Ph.D., vice president of research and development, Ecolab Life Sciences. 'This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab's innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market.'
Article content
Biopharma and contract manufacturing organizations are already leveraging Ecolab's Bioprocessing Applications Lab to help accelerate speed and enhance manufacturing efficiencies through lifecycle studies. The lab can initiate studies and deliver results within weeks, facilitating a faster route to market while providing customers with access to raw data and bench-level operations for transparency and collaboration.
Article content
The new lab complements Ecolab's existing European Applications and Research & Development Lab, in Wales, U.K., and is part of the Ecolab Life Sciences Pharma Center of Excellence, a multi-million dollar investment which also includes an interactive learning space, The Xchange customer experience center, and an API (Active Pharmaceutical Ingredient) and excipient manufacturing facility.
Article content
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab's innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Septic System Owners Are Ditching the Old Way of Cleaning Toilets
You're already cleaning your toilet — why not clean your septic system too, with the same flush? The first and only 2-in-1 cleaner that cleans your toilet and treats your septic system at the same time. Instead of using harsh chemicals that can harm septic health, this foaming formula uses Dr. Pooper's proven Accelerator by Dr. Pooper® bio-technology to safely break down septic solids. Hockley, TX - Jun 3, 2025 - In a market filled with 'single-purpose' bathroom cleaners, the new Accelerator by Dr. Pooper® Toilet Bowl & Septic Cleaner is simplifying routines — and septic system maintenance — with a smarter, dual-function approach. What makes this product so different? It's the first and only 2-in-1 cleaner that cleans your toilet and treats your septic system at the same time. Instead of using harsh chemicals that can harm septic health, this foaming formula uses Dr. Pooper's proven Accelerator by Dr. Pooper® bio-technology to safely break down solids in your pipes, tank, and drain field. 'It's the easiest and most effective septic maintenance you'll ever do,' said Chris Denny, CEO and co-founder of Dr. Pooper. 'You're already cleaning your toilet — why not clean your septic system too, with the same flush?' The 2-in-1 Toilet Bowl & Septic Cleaner has quickly become a favorite among homeowners with septic systems, especially those looking to: And because it's totally non-toxic, there's no risk to pets, kids, or groundwater. The 2-in-1 Toilet Bowl & Septic Cleaner is available now on Media Contact Company Name: Dr. Pooper Enterprise LLC Contact Person: Chris Denny Email: Send Email Phone: 8323016075 Address: 27122 FM 2920 City: Hockley State: Texas Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
FTI Consulting: A Hidden Gem or Just Fine?
Explore the exciting world of FTI Consulting (NYSE: FCN) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of April 28, 2025. The video was published on Jun. 3, 2025. Should you invest $1,000 in FTI Consulting right now? Before you buy stock in FTI Consulting, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and FTI Consulting wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor 's total average return is987% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
an hour ago
- Globe and Mail
Trump administration scraps guidance on emergency abortions
The Trump administration announced on Tuesday that it would revoke guidance to the nation's hospitals that directed them to provide emergency abortions for women when they are necessary to stabilize their medical condition. That guidance was issued to hospitals in 2022, weeks after the U.S. Supreme Court upended national abortion rights in the U.S. It was an effort by the Biden administration to preserve abortion access for extreme cases in which women were experiencing medical emergencies and needed an abortion to prevent organ loss or severe hemorrhaging, among other serious complications. The Biden administration had argued that hospitals – including states with near-total bans – needed to provide emergency abortions under the Emergency Medical Treatment and Active Labor Act. That law requires emergency rooms that receive Medicare dollars to provide an exam and stabilizing treatment for all patients. Nearly all emergency rooms in the U.S. rely on Medicare funds. More people in U.S. are obtaining abortions, but fewer are traveling to other states for it, survey finds The Trump administration announced on Tuesday that it would no longer enforce that policy. The move prompted concerns from some doctors and abortion rights advocates that women will not get emergency abortions in states with strict bans. 'The Trump Administration would rather women die in emergency rooms than receive life-saving abortions,' Nancy Northup, president and CEO of the Center for Reproductive Rights, said in a statement. 'In pulling back guidance, this administration is feeding the fear and confusion that already exists at hospitals in every state where abortion is banned. Hospitals need more guidance, not less, to stop them from turning away patients experiencing pregnancy crises.' Anti-abortion advocates praised the move, however. Marjorie Dannenfelser, president of SBA Pro-Life America, said in a statement that the Biden-era policy had been a way to expand abortion access in states where it was banned. 'Democrats have created confusion on this fact to justify their extremely unpopular agenda for all-trimester abortion,' she said. 'In situations where every minute counts, their lies lead to delayed care and put women in needless, unacceptable danger.' An Associated Press investigation last year found that, even with the Biden administration's guidance, dozens of pregnant women were being turned away from emergency rooms, including some who needed emergency abortions. The Centers for Medicare and Medicaid Services, which investigates hospitals that are not in compliance, said in a statement that it will continue to enforce the federal law that, 'including for identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy.' But CMS added that it would also 'rectify any perceived legal confusion and instability created by the former administration's actions.' The Biden administration sued Idaho over its abortion law that initially only allowed abortions to save the life of the mother. The federal government had argued before the U.S. Supreme Court last year that Idaho's law was in conflict with the federal law, which requires stabilizing treatment that prevents a patient's condition from worsening. The U.S. Supreme Court issued a procedural ruling in the case last year that left key questions unanswered about whether doctors in abortion ban states can terminate pregnancies when a woman is at risk of serious infection, organ loss or hemorrhage.
